Manufacturer
257 recalls in our database name Hospira, Inc. as the manufacturing or recalling firm.
Of the 257 recalls from Hospira, Inc. we have scored against our rubric, 18 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 104 (40%) are Severe.
Which agencies issued them
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Hospira Inc. is recalling 325,056 bags of 0.9% Sodium Chloride Injection USP, 100 mL, due to a potential lack of assurance of sterility.
Hospira Inc. is recalling 56,854 units of 0.9% Sodium Chloride Irrigation, USP, 3000 mL, due to a potential leak from the administration port that compromises sterility.
Hospira is recalling 63,900 vials of Furosemide Injection USP because a loose crimp on the vial cap may compromise sterility.
Hospira Inc. is recalling 273,925 vials of Propofol Injectable Emulsion because visible particulate matter was found during inspection.
Hospira is recalling 31,326 vials of Carboplatin Injection due to visible crystals found during inspection. The product is distributed nationwide and in Puerto Rico.
Hospira Inc. is recalling 23,315 vials of Carboplatin Injection due to visible particulates identified as Carboplatin crystals.
Hospira is recalling specific lots of Epinephrine Injection USP because they may contain glass particles.
Hospira is recalling 297,833 Plum A+ infusion pumps because a door roller assembly may break, causing unrestricted flow or over-delivery of IV fluids.
Hospira is recalling 180 Plum A+ Hyperbaric Infusion Pumps because a door roller assembly may break, potentially causing unrestricted flow or over-delivery of medication.
Hospira is recalling 28,599 Plum A+3 infusion pumps worldwide because a door roller assembly may break, potentially causing unrestricted flow or over-delivery of IV medication.
Hospira is recalling 145,400 vials of Nalbuphine Hydrochloride Injection because loose crimps and missing stoppers prevent assurance of sterility.
Hospira is recalling Lidocaine Hydrochloride Injection vials because visible particulate matter embedded in the glass wall may dislodge into the product.
Hospira is recalling Plum A+ infusion pumps because the volume control knob may reverse the alarm volume direction.
Hospira is recalling Plum A+ single channel infusion pumps because the volume control knob may function in reverse, causing alarm volume to increase when turned clockwise.
Hospira is recalling Plum A+ Hyperbaric Infusion Pumps because the volume control knob may function in reverse, causing alarm volume to increase when turned clockwise.
Hospira is recalling 216,880 units of Hydromorphone Hydrochloride Injection because the prefilled cartridges were found to be overfilled, containing more than the labeled 1 mL volume.
Hospira is recalling Symbiq Two Channel Infusers because the touchscreen may fail to respond or register incorrect values, potentially causing medication delivery errors.
Hospira is recalling 19,614 Symbiq One Channel Infusion Pumps because the touchscreen may fail to respond or register incorrect values, potentially leading to medication dosing errors.
Hospira Inc. is recalling 148,630 vials of Propofol Injectable Emulsion because a single visible particulate was found in sample bottles during inspection.
Hospira Inc. is recalling Carboplatin Injection vials because visible particles are embedded in the glass neck, posing a risk of dislodging into the solution.
Hospira Inc. is recalling 191,094 units of Empty Evacuated Containers (250 mL and 1000 mL) because an embedded iron oxide glass defect may break off into the solution.
Hospira Inc. is recalling Methotrexate Injection vials because visible particles embedded in the glass neck may dislodge into the solution.
Hospira is recalling 210 vials of Cytarabine Injection because visible particles embedded in the glass neck may dislodge into the solution.
Hospira Inc. is recalling Paclitaxel Injection vials because visible particles are embedded in the glass at the neck. The particles may dislodge into the solution.
Hospira is recalling sterile empty vials and injectors because they may leak during filling and administration. The recall covers products distributed in the US, Canada, Costa Rica, and the Virgin Islands.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
Hospira
American pharmaceutical company
Source: Wikidata (Q1470525), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.